Webinar: RWE, CAR-T and Cancer – New Methods for Comparative Effectiveness
August 29th, 1-2pm CET
About the webinar
With the increasing use of new regulatory tools, like the FDA’s breakthrough therapy designation, there are increasing demands for European health technology assessors (HTAs) to make an accurate assessment of the long-term value and performance of CAR-T therapies from smaller datasets and shorter outcomes.
This webinar will highlight our recent publication in the BMJ, sponsored by ZIN, which showcases a novel approach to harnessing RWE and develops a longitudinal data set that can be used for effectiveness measures, even in orphan conditions.
As well, we will kickoff our new research project in Diffuse large B-cell lymphoma (DLBCL) and describe how we will leverage our methodology to measure the effectiveness of the various options for treatment, both in emerging CAR-T treatments, as well as existing chemotherapy regimes and bone-marrow transplants.
Anja Schiel, PhD
Lead Methodologist in Regulatory and Pharmacoeconomic Statistics
Norwegian Medicines Agency (NoMA)
Amr Makady PharmD, PhD
Project Leader & Senior Policy Advisor
Zorginstituut Nederland (ZIN)